Meeting
2016 ASCO Annual Meeting
Phase IB Study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).
Authors
Diwakar Davar
University of Pittsburgh Medical Center, Pittsburgh, PA
Diwakar Davar , Hong Wang , Joe-Marc Chauvin , Zhaojun Sun , Ornella Pagliano , Amy Rose , Carrie Muniz , Cindy Sander , Julien J. Fourcade , Uma N. M. Rao , Nageatte Ibrahim , Scot Ebbinghaus , Hussein Abdul-Hassan Tawbi , Ahmad A. Tarhini , John M. Kirkwood , Hassane M. Zarour , Giuseppe Russo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02112032
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9539)
DOI
10.1200/JCO.2016.34.15_suppl.9539
Abstract #
9539
Poster Bd #
144
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
First Author: Diwakar Davar
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover
Poster
2023 ASCO Annual Meeting
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.
First Author: Paolo Antonio Ascierto
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin